文献速递细菌感染、耐药与抗菌药物新发突发、热带与寄生虫病

新冠后台湾儿童大环内酯耐药肺炎支原体新序列型3亚克隆出现

Emergence of Novel Macrolide-Resistant Mycoplasma pneumoniae Sequence Type 3 Subclades in Children after COVID-19 Pandemic, Taiwan.
PubMed 文献 · Emerg Infect Dis · 2026-01-01

该多中心研究评估新冠后台湾儿童肺炎支原体趋势,发现2024年发病率较2019年峰值翻倍,ICU入住和中枢神经系统并发症显著增加,并鉴定出4个新亚克隆取代疫情前谱系,其中1个与重症相关。

要点

  • 新冠后肺炎支原体再流行,2024年儿童发病率达546/10万,ICU入住和CNS并发症大幅上升。
  • 2023-2024队列(n=226)中,中性粒细胞>7000/μL、血小板>400×10^3/μL、胸腔积液和CNS受累为ICU入住危险因素。
  • 698株基因组分析显示4个新亚克隆取代疫情前谱系,1个与重症相关,提示耐药和嗜神经谱系演化。

核心结论

  • 新冠后台湾儿童肺炎支原体再流行严重,出现大环内酯耐药新亚克隆,其中1个与重症相关,需加强监测。

研究设计与样本

  • 多中心研究评估儿童肺炎支原体趋势,含2023-2024年前瞻性队列(n=226)和698株基因组系统发育分析。

主要发现

  • 2024年发病率546/10万,较2019年峰值翻倍;ICU入住10.9/10万,增加2.2倍;CNS并发症6.1/10万,激增13.7倍。
  • 2023-2024队列中ICU入住危险因素:中性粒细胞>7000/μL(aOR 6.2 [95%CI 1.3-29.9])、血小板>400×10^3/μL(aOR 12.5 [95%CI 2.7-57.9])、胸腔积液(aOR 9.7 [95%CI 1.6-58.1])、CNS受累(aOR 27.9 [95%CI 4.1-188.3])。
  • 698株基因组分析显示4个新亚克隆到2024年中期取代疫情前谱系,1个亚克隆与重症结局相关。

临床怎么用

  • 临床应警惕新冠后儿童肺炎支原体再流行,对中性粒细胞>7000/μL、血小板>400×10^3/μL、胸腔积液或CNS受累者加强重症监护。
  • 需关注大环内酯耐药和嗜神经新亚克隆,强化耐药监测和分子流行病学监测。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Post-COVID-19 pandemic Mycoplasma pneumoniae resurgences have occurred globally and have been particularly severe in Taiwan. We conducted a multicenter study to assess M. pneumoniae trends in children. Compared with the 2019 peak, 2024 data revealed a doubling of incidence (546/100,000 population), a 2.2-fold increase in intensive care unit admissions (10.9/100,000 population), and a 13.7-fold surge in central nervous system complications (6.1/100,000 population). In a 2023-2024 prospective cohort (n = 226), intensive care unit admission risk factors were neutrophils >7,000/μL (adjusted odds ratio [aOR] 6.2 [95% CI 1.3-29.9]), platelets >400 × 103/μL (aOR 12.5 [95% CI 2.7-57.9]), pleural effusion (aOR 9.7 [95% CI 1.6-58.1]), and central nervous system involvement (aOR 27.9 [95% CI 4.1-188.3]). Phylogenetic analysis of 698 genomes demonstrated that 4 emerging subclades replaced pre-COVID-19 lineages by mid-2024; 1 subclade was associated with severe outcomes, highlighting evolving resistant, neurotropic lineages and calling for enhanced surveillance.

来源:Emerg Infect Dis,查看原文。版权归原作者所有。

引用

  1. Hsieh YC, Lin CC, Wu JW, et al. Emergence of Novel Macrolide-Resistant Mycoplasma pneumoniae Sequence Type 3 Subclades in Children after COVID-19 Pandemic, Taiwan. Emerg Infect Dis. 2026. PMID: 42909847. doi:10.3201/eid3211.260439

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。